X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse IPCA Labs with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs TEVA PHARMA (Israel) - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 IPCA LABS   TEVA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
TEVA PHARMA
Dec-13
IPCA LABS/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6432,665-   
Low Rs5032,315-   
Sales per share (Unadj.) Rs254.41,529.5-  
Earnings per share (Unadj.) Rs16.195.5-  
Cash flow per share (Unadj.) Rs29.8219.2-  
Dividends per share (Unadj.) Rs1.0083.64-  
Dividend yield (eoy) %0.23.4 5.2%  
Book value per share (Unadj.) Rs194.61,699.0-  
Shares outstanding (eoy) m126.20848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.31.6 138.3%   
Avg P/E ratio x35.726.1 136.8%  
P/CF ratio (eoy) x19.211.4 169.4%  
Price / Book Value ratio x2.91.5 200.9%  
Dividend payout %6.287.5 7.1%   
Avg Mkt Cap Rs m72,3002,111,647 3.4%   
No. of employees `00013.344.9 29.6%   
Total wages/salary Rs m6,9600-   
Avg. sales/employee Rs Th2,413.528,858.6 8.4%   
Avg. wages/employee Rs Th523.20-   
Avg. net profit/employee Rs Th152.41,802.8 8.5%   
INCOME DATA
Net Sales Rs m32,1061,297,049 2.5%  
Other income Rs m2260-   
Total revenues Rs m32,3321,297,049 2.5%   
Gross profit Rs m4,448355,198 1.3%  
Depreciation Rs m1,730104,842 1.6%   
Interest Rs m24125,476 0.9%   
Profit before tax Rs m2,703224,880 1.2%   
Minority Interest Rs m01,022 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-147,621 0.0%   
Tax Rs m675-2,746 -24.6%   
Profit after tax Rs m2,02881,026 2.5%  
Gross profit margin %13.927.4 50.6%  
Effective tax rate %25.0-1.2 -2,045.9%   
Net profit margin %6.36.2 101.1%  
BALANCE SHEET DATA
Current assets Rs m17,340876,022 2.0%   
Current liabilities Rs m9,559763,965 1.3%   
Net working cap to sales %24.28.6 280.5%  
Current ratio x1.81.1 158.2%  
Inventory Days Days10091 110.5%  
Debtors Days Days5796 59.3%  
Net fixed assets Rs m20,779423,645 4.9%   
Share capital Rs m2523,193 7.9%   
"Free" reserves Rs m24,4990-   
Net worth Rs m24,5531,440,775 1.7%   
Long term debt Rs m3,517663,210 0.5%   
Total assets Rs m39,5952,964,172 1.3%  
Interest coverage x12.29.8 124.4%   
Debt to equity ratio x0.10.5 31.1%  
Sales to assets ratio x0.80.4 185.3%   
Return on assets %5.73.6 159.5%  
Return on equity %8.35.6 146.9%  
Return on capital %10.54.9 212.7%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Net fx Rs m9,7900-   
CASH FLOW
From Operations Rs m2,764206,682 1.3%  
From Investments Rs m-1,432-73,236 2.0%  
From Financial Activity Rs m-1,591-247,930 0.6%  
Net Cashflow Rs m-259-114,483 0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare IPCA LABS With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare IPCA LABS With: AJANTA PHARMA  SUN PHARMA  PANACEA BIOTECH  UNICHEM LAB  AUROBINDO PHARMA  



Today's Market

Of Rising Stock Markets, Reduction in Government's Additional Borrowing, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a strong note yesterday. At the closing bell yesterday, the BSE Sensex crossed its 35,000 mark for the first time and stood higher by 311 points (up 0.9%).

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jan 17, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS